Akers Biosciences Share Discussion Threads

[wigwammer] 12/5/2016 20:05

Back on planet earth, gormally comes across well, imo:http://www.akersbio.com/investor-center/earnings-center#Conference-Call

[wigwammer] 12/5/2016 16:03

"The company shares will go to a premium and hit a takeover trail."What?

[norbus] 12/5/2016 11:28

mcm

You are right but missing the main point. AKR has a new controlling boss, who will fix it through a shell operation. I guess he only bought in for the quote. That was what I expected Nicolette to do, The company shares will go to a premium and hit a takeover trail. There will be money to make off this level.

[norbus] 12/5/2016 08:46

Results out today; net current assets less liabilities~$3m, loss Q1 $1.5m Clearly control changed hands by the back door without a takeover bid. You guys may get something back, if the new man is a winner

[mcmather] 11/5/2016 23:11

In terms of longevity and shareholder (erosion) value, is there a worse head of a 'commercial' enterprise in the history of aim than Dr Raymond F. Akers Jr., Ph.D.? Genuine question by the way.

And this was his latest comment following his recent demotion:
Raymond F. Akers, Jr., Co-founder, commented: "I look forward to continuing to communicate the Akers Bio story to the investment community". If it wasn't Dr Walt it would be unbelievable.


Q1 2016 results tomorrow....

[norbus] 26/4/2016 15:37

They have TWO Chairmen
Raymond Akers, executive chairman of Akers Biosciences Inc
Thomas Knox, Chairman, commented:

They sit at opposite ends of the table farting the boardroom aromatically

[mcmather] 26/4/2016 09:56

Still catching with things algernon but it's been a long time coming Dr Walt.

[algernon2] 26/4/2016 09:46

Thomas Knox, Chairman, commented:

"Having our recently appointed CEO focusing successfully on product commercialization and operations enables us to deploy the strengths of the Board of Directors more effectively; I am pleased that this allows Dr. Akers to focus on accelerating the development of our pipeline of rapid diagnostic tests."

[werewolfie] 01/4/2016 10:35

Yes Ray is very good at casting a rosy glow to deflect from the grim realities. Glad I sold 2 years ago. 9m loss ffs

[proactivest] 01/4/2016 10:29

Video interview with Ray Akers



Raymond Akers, executive chairman of Akers Biosciences Inc (NASDAQ:AKER, LON:AKR) says the company has “paved the way for significant sales of our flagship product both in the US and China” and has “already started to see the results”.
The firm announced today that orders for its rapid heparin allergy test total more than US$3mln, with $2.5mln from China, as well as a 70% rise in demand from the US in the first quarter.
Akers says, with the expanded order book, that he expects to be cash generative in the second half of this year.

[norbus] 30/3/2016 13:29

You did; $4m in the B/S then its over; laid to rest. Sure mcm will want to read the B/S; Bad debt from related party >$2m , Legal $.75m

[werewolfie] 30/3/2016 11:12

$9 million loss? Did I read that correctly?

[norbus] 27/3/2016 07:44

mcm

If you need a laugh, do not miss the snake oil pitch from Akers to the Knackers Raymond Akers PHD., Esquire. Stellar year ahead

[proactivest] 24/3/2016 15:46

Video interview with Ray Akers



Raymond Akers, founder and executive chairman of Akers Biosciences Inc (NASDAQ:AKER, LON:AKR), says “this is gonna be a great year” after a “blazing start” to 2016.
The diagnostic test maker has been granted a US patent for the technology at the heart of a test that detects an allergy to the blood thinning drug Heparin.
The patent was just the tip of the iceberg as the group expands its reach. “We now have distribution in 33 countries around the world," says Akers who added the US$2.5mln order it received from China was a “taste of things to come.”

[norbus] 23/3/2016 08:07

Patents do not create or increase sales; If a proposition in China USA patent is not worth the paper, imo

[mcmather] 17/3/2016 09:18

There is very likely only one place this is heading whilst the perennial destroyer of shareholder value, Dr Raymond F. Akers Jr., Ph.D., is at the helm but do you mean AIM or Nasdaq?

[buywell3] 17/3/2016 09:07

Chart now looking set for another leg down ?

[algernon2] 16/3/2016 12:22

"The Company will hold a conference call on 30 March 2016 at 2:00 p.m. BST (09:00 a.m. EDT). Akers Bio's Co-Founder and Executive Chairman, Raymond F. Akers, Jr. PhD, and Vice President of Finance, Gary Rauch, will host the call and be available during a question-and-answer session......"

So who will be calling in to pose all our unanswered questions: Mcmather will you?
Anyone?

[norbus] 11/3/2016 09:24

mcm

$5m is hardly going to keep the operation for long; I see a story developing for the next NASDAQ funding

[buywell2] 10/3/2016 22:56

............... The State of Big Pharma today in 2016 .................


Cancer drugs are the most expensive of them all at around $200,000 per patient per year.

There is no cure for cancer , diabetes (type 1 ) or Alzheimer's to name but 3 diseases.

However it has now been found that many different subsets of breast cancers exist ,



These different subsets are caused by an individuals genetic mutations.

Thus it is not a far stretch to believe that as molecular diagnostics , DNA testing and sequencing improves and gets better with ever better machines and technology .... that many subsets of other cancers will be identified. eg recently



It follows that in the future different cancer drug compounds will be made to treat the different subset types.

However

The cost of making a new drug is hitting around $5 Billion according to Forbes



Plus the time taken can be up to 15 years

Plus many drugs get withdrawn after FDA approval due to toxicity issues

Then litigation kicks in and the costs today run due to class actions at around $1 to $2 Billions plus the wasted development costs and bad PR costs

Even a BIG Pharma could not stand 2 such disasters within 12 month period I would suggest.

So as it stands the FDA rules re the use of 2 animal types , one rodent one not, for toxicity testing , lasting around 3 months max ,


These outdated regulations have existed for over half a century could result in some BIG names getting into trouble as things stand.

Genetic human mutations in cancers .... means animal use is the pre-clinical arena of new drug development is now a complete and utter waste of time.

[mcmather] 10/3/2016 20:06

Another failure by Dr Raymond F. Akers Jr., Ph.D. is that part of the reason for the nasdaq listing was to increase overall liquidity of the stock. Notwithstanding the nominal value of the below (few) trades today, there is a difference of 38.50p between the 'buys' and the sell. That is an actual 'spread' of 28.50%!?

12:38:53 10-Mar-2016 110.00 1,612 1,773.20
10:32:12 10-Mar-2016 148.50 250 371.25
09:12:14 10-Mar-2016 148.50 30 44.55

[mcmather] 07/3/2016 14:46

True. But that has nearly always been the case since AKR came to AIM in 2002. Dr Raymond F. Akers Jr., Ph.D. has often spoken about game changing, potential multi-million unit markets / deals but has yet to deliver.

If this finally comes good, that will be a bonus. But until Dr Raymond F. Akers Jr., Ph.D. and his board show a due regard to the shareholders of this publicly listed company they will be considered accordingly and this, I surmise, also by their fellow americans who participated in the Nasdaq IPO which Dr Raymond F. Akers Jr., Ph.D. sold to the US public at $5.50 a share.

Appreciate that there is scope here to potentially make some money - which is why, after all, we are all here - if buying at these levels. My postings are simply to highlight that, based on my reviewing of matters here over the years, what Dr Raymond F. Akers Jr., Ph.D. utters should be taken with a pinch of salt. Which should not be the case for a Co-founder and Executive Chairman of a publicly listed enterprise.

[wigwammer] 07/3/2016 14:28

Quite possibly a softener. In the interview he seems keen to move onto discussing Q116 before full year numbers are out. Then again, we may get further detail on novotek deal, us sales penetration and breathscan at time of full year figures.To repeat, sub 1p looked like capitulation. He doesn't have to do much to move the needle.

[mcmather] 07/3/2016 13:46

Not a massive amount of interest in the shares either here or in the US WW but nasdaq does certainly appear to be the lead market.

Value of shares over here has been miniscule but the share price has 'risen' 50%...

Usual caution I reckon; the results will be here shortly and they will apparently show another disgraceful effort by this board led by Dr Raymond F. Akers Jr., Ph.D.

The recent 'order' appears promising at first appearance; but this has been said many times down the years with Tri-Cholesterol orders, Revelar orders, etc, none of which then materialised...

My suspicion is that this is a simple 'softener' for another woeful annual performance by Dr Walt but during which he will once again have pocketed a remuneration package of approx $350k; which is an absolute disgrace for a proven, consistent failure (his job being to oversee value for the shareholders of this publicly listed enterprise).